Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Stroke Management Devices Market $13.5 Billion by 2029

The global market for stroke management devices anticipated to attain $13.5 billion by 2029, growing steadily at a CAGR of 6.8% over the forecast period, driven by increasing incidence of stroke in developed countries, growing preference for minimally invasive surgical procedures, and recent technological advances.

Global Stroke Management Devices Market

Research and development have significantly advanced stroke care, and advancements in stroke technology, research and clinical expertise are continually improving outcomes and quality of life for stroke patients.

According to the World Health Organization (WHO), 15 million people suffer strokes worldwide each year, resulting in 5 million deaths and another 5 million patients left permanently disabled. High blood pressure contributes to more than 12.7 million strokes worldwide.

Strokes have two different causes. The most common, causing approximately 85-87% of strokes, is blockage of an artery, usually by a blood clot, which results in an ischemic stroke. The other 15% hemorrhagic strokes occur when an artery in the brain ruptures, often as a result of long-term hypertension.

  • Ischemic strokes can be further categorized as thrombotic or embolic. Thrombotic strokes occur when a blood clot forms in a diseased vessel within the brain, often as a result of atherosclerotic plaque rupture. Embolic strokes are the result of a blood clot that travels from another part of the body and lodges in an otherwise normal cranial blood vessel.
    • Acute ischemic stroke is one of the major sources of morbidity and mortality in the industrialized countries. According to the National Institute of Neurological Disorders and Stroke (NNDS), the cost of stroke to the United States is staggering and medical devices have a key role in addressing and ameliorating this condition.

Because prompt evaluation and treatment of stroke has a profound effect on patient outcomes, there has been a strong focus on improving recognition and speeding response. It is vital to diagnose the type of stroke accurately, since the treatments for the two types are very different.

  • Angioplasty, with or without vascular stenting, is a minimally invasive procedure. It is used to improve blood flow when a vein or artery is too narrow or blocked. It is usually done in an interventional radiology suite rather than operating room.
    • Carotid angioplasty and stenting are procedures that open clogged arteries to restore blood flow to the brain, often performed to treat or prevent strokes.

There are two main options to treat ischemic strokes. The thrombolytic medications to dissolve the clot, and the mechanical clot removal, which can be performed with two different types of devices: stent retrievers and aspiration catheters.

  • Most of the healthcare centers with 24/7 facility for mechanical clot removal tend to favor this option instead. The results of interventional procedures appear to be superior to those of thrombolysis, given the lower associated incidence of intracranial hemorrhage and the ability to conduct the procedure as much as 24 hours after symptom onset.
  • The various techniques and approaches for mechanical thrombolysis (MT) includes thrombus disruption, immediate flow restoration with self-expandable stents, and thrombectomy.
    • Mechanical thrombectomy devices seek to salvage ischemic, but not yet fully infarcted, brain by restoring perfusion through the initially occluded artery.
      • Mechanical thrombectomy devices comprise a wide array of endovascular tools cleared for removing thrombi from the neurovasculature in acute ischemic stroke patients.
  • The vascular closure devices are used in patients receiving thrombolytic therapy is safe and effectively achieves hemostasis. Traditionally, hemostasis at the access site has been achieved via manual compression, the gold standard. However, a wide array of vascular access closure devices have been created to assist the proceduralist in achieving hemostasis.

The global market for stroke management devices research report provides market size ($million 2019 to 2029), market share analysis, growth trends and forecast (CAGR%, 2023 to 2029).

The global market for stroke management devices segmentation is based on product [circulatory disorder management devices (angioplasty catheters, atherectomy catheters and devices, stents), embolic protection and embolus / thrombus removal devices (catheter-directed thrombolysis catheters, embolus / thrombus removal catheters, others), surgical procedure devices (vascular access site closure devices)], and geography.

  • Based on the broader product categories, the circulatory disorder management devices segment accounted for the largest share of the total market, whereas the embolic protection and embolus / thrombus removal devices segment anticipated to witness the fastest growth rate in the coming years.
  • The stents sub-segment dominated the circulatory disorder management devices segment, while the angioplasty catheters sub-segment predicted to grow at the fastest CAGR during the forecast period.
    • Atherosclerotic disease of the extracranial carotid artery accounts for approximately 30% of all ischemic strokes. The last decade has seen the development of nickel titanium self-expandable stents (SES).
      • These stents, in contrast to balloon-mounted stents, allow better navigability and deployment in tortuous vessels and therefore are optimal for the cerebral circulation. SES were initially used for stent-assisted coil embolization of intracranial aneurysms and for treatment of intracranial stenosis.
    • Angiography is currently one of the most common procedures performed across many specialties including diagnostic and interventional cardiology, vascular surgery and interventional radiology.
      • Carotid angioplasty is often combined with another procedure called stenting.
  • On the other hand, the catheter-directed thrombolysis catheters sub-segment registered highest revenue of the embolic protection and embolus / thrombus removal devices segment, while the embolus / thrombus removal catheters sub-segment estimated to grow nearly at double-digit rate over the next few years.
    • Following the recent publications demonstrating the efficacy of neurovascular thrombectomy for treating acute ischemic strokes up to 24 hours after symptom onset, the American Heart Association (AHA) updated its guidelines, extending the recommended treatment window from six hours to 24. As a result of this extended window, mechanical thrombectomy devices are being used in a greater proportion of stroke patients, driving strong growth in procedure volumes.

The global market for stroke management devices research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geography, the North America followed by the Europe region accounted for the largest share of the product revenues, and also forecast to maintain its leadership positions over the forecast period.
    • Epidemiologic studies indicate that 82-92% of strokes in the United States are ischemic. According to the AHA, Stroke is the No. 5 cause of death and a leading cause of disability in the United States.
  • In the United States, stroke is now the fifth leading cause of death, behind heart disease and cancer. The Centers for Disease Control and Prevention (CDC) report that 795,000 people suffer strokes annually in the U.S. About 610,000 of these are first or new strokes.
    • Nearly three-quarters of all strokes occur in people over the age of 65; however, strokes can and do occur at any age.
      • American Stroke Association developed the F.A.S.T. campaign to help the general public identify strokes rapidly, with the goal of improving outcomes.
  • Stroke is the second most common single cause of death in Europe and the leading cause of long-term disability. Every year, up to 1.3 million persons in Europe suffer a first-ever stroke.
    • The number of people living with stroke is estimated to increase by 27% between 2017 and 2047 in the European Union (EU), mainly because of population ageing and improved survival rates.
      • In developed countries, the incidence of stroke is declining due to efforts to lower blood pressure and reduce smoking. However, the overall rate of stroke remains high due to aging populations.

In addition, the global market for stroke management devices report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for stroke management devices and profiled in this report include Abbott Laboratories, Inc., Boston Scientific Corporation, Brawn Medical Ltd., Eclipse Medical, Inc., GE Healthcare, Hitachi Medical Corporation, InspireMD, Inc., Jan Medical, Inc., Johnson & Johnson, LifeTech Scientific Corporation, Medtronic plc, Penumbra, Inc., Philips Healthcare, Rapid Medical Ltd., Siemens Healthineers AG, and Stryker Corporation.

  • Product
    • Circulatory Disorder Management Devices
      • Angioplasty Catheters
      • Atherectomy Catheters and Devices
      • Stents
    • Embolic Protection and Embolus / Thrombus Removal Devices
      • Catheter-directed Thrombolysis Catheters
      • Embolus / Thrombus Removal Catheters
      • Others
    • Surgical Procedure Devices
      • Vascular Access Site Closure Devices
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • Boston Scientific Corporation
    • Brawn Medical Ltd.
    • Eclipse Medical, Inc.
    • GE Healthcare
    • Hitachi Medical Corporation
    • InspireMD, Inc.
    • Jan Medical, Inc.
    • Johnson & Johnson
    • LifeTech Scientific Corporation
    • Medtronic plc
    • Penumbra, Inc.
    • Philips Healthcare
    • Rapid Medical Ltd.
    • Siemens Healthineers AG
    • Stryker Corporation

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com